Matthew Brown (left) and Steve May wrote their report on Anchitheriomys buceei for Palaeontologia Electronica. Photo courtesy of UT Jackson School of Geosciences

The legend of a treasured gas station chain continues with a new chapter: a rediscovered beaver fossil is being named after Buc-ee’s.

The ancient animal was named Anchitheriomys buceei (A. buceei) by Steve May, a research associate at the University of Texas Jackson School of Geosciences and lead author of the Palaeontologia Electronica paper that describes the beaver.

A. buceei fossils were rediscovered by researchers in UT Austin’s collections and include fossils from six different Texas sites. May decided to name A. buceei after Buc-ee’s after spotting a “This is Beaver Country” billboard in 2020 that reminded him of the fossils he was studying at the time.

Though Buc-ee’s was founded in 1982, CEO Arch “Beaver” Alpin III said in a press release that his business’ history is longer than he thought, and that he may “need to rethink [their] beginnings.”

Occurrences of A. buceei can be found between 15 and 22 million years ago along the state’s gulf coast. At first glance, they don’t appear much different from current native Texas beavers. But according to the report’s co-author Matthew Brown, who is also the director of the Jackson School’s vertebrate paleontology collections, they are nearly 30 percent bigger than today’s beavers.

A partial skull fossil of the beaver was originally collected in 1941 by paleontologists. One of the original finders was Texas A&M University museum curator Curtis Hesse, who passed away four years later before he could name it a new species and publish his study.

More information about A. buceei can be found on UT Austin’s website.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.